TLR7 and cancer: Of note, the majority of clinical trials, phases (1, 2 and 3), have evaluated TLR ligands as immune adjuvants to improve the immunogenicity of various cancer or immunomodulatory vaccines; such as TLR3 agonist in low grade B-cell lymphoma, melanoma and metastatic colon cancer and TLR7 agonist in Hepatitis B vaccine (HBV) and Human papilloma virus (HPV) vaccine[11].